Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Aytu Biopharma (AYTU) Receivables - Net (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Receivables - Net for 11 consecutive years, with $30.9 million as the latest value for Q4 2025.

  • Quarterly Receivables - Net rose 21.73% to $30.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.9 million through Dec 2025, up 21.73% year-over-year, with the annual reading at $32.3 million for FY2025, 37.48% up from the prior year.
  • Receivables - Net for Q4 2025 was $30.9 million at Aytu Biopharma, down from $33.2 million in the prior quarter.
  • The five-year high for Receivables - Net was $35.8 million in Q1 2025, with the low at $21.6 million in Q3 2021.
  • Average Receivables - Net over 5 years is $28.3 million, with a median of $29.4 million recorded in 2023.
  • The sharpest move saw Receivables - Net surged 438.35% in 2021, then fell 25.83% in 2024.
  • Over 5 years, Receivables - Net stood at $23.0 million in 2021, then rose by 10.92% to $25.5 million in 2022, then increased by 15.31% to $29.4 million in 2023, then fell by 13.6% to $25.4 million in 2024, then grew by 21.73% to $30.9 million in 2025.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $30.9 million, $33.2 million, and $31.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.